Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer

Brink, Ingo; Schumacher, T.; Mix, Michael; Rühland, Svenja; Stoelben, Erich; Digel, Werner; Henke, Michael; Ghanem, Nadir; Moser, E.; Nitzsche, Egbert U.

doi:10.1007/s00259-004-1606-x

Cited by 211 publications

(142 citation statements)

References 24 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…In a study including 120 SCLC patients, results after FDG-PET were compared with those of conventional staging procedure. Only 1 out of the 120 patients was incorrectly staged by FDG-PET (13). In another study with 18 patients, FDG-PET showed a more extensive disease in 2 of the 3 patients for which FDG-PET and conventional staging disagreed (14).…”

Section: Discussionmentioning

confidence: 99%

New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases

Dayen¹,

Debieuvre²,

Molinier³

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: The French College of General Hospital Respiratory Physicians conducted two studies that consecutively included all patients followed in participating general hospitals for primary small cell (SCLC) or non-small cell (NSCLC) lung cancer diagnosed in 2000 and 2010. These studies allow descriptive statistics and outcome assessment for SCLC and NSCLC separately and comparison over a 10-year period.Methods: A standardised form was completed for each patient at inclusion. Then, vital status was collected.

show abstract

Section: Discussionmentioning

confidence: 99%

New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases

Dayen¹,

Debieuvre²,

Molinier³

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…Literatürde yeni tanı alan KHAK olgularında FDG PET'in evreleme ve klinik tedavi protokollerinde %10-33 oranında değişikliğe neden olabileceği bildirilmiştir (2). 120 KHAK olgusunu kapsayan bir çalışmada FDG PET konvansiyonel görüntüleme prosedürleri ile kıyaslandığında; 10 olgunun evresinde artış, 3 olgunun evresinde ise düşme dikkati çekmiştir (25). Bir başka çalışmada konvansiyonel yöntemler ile sınırlı hastalık kategorisinde değerlendirilen 26 olgudan 4'ü (%15) FDG PET sonrası yaygın hastalık kategorisinde değerlendirilirken, yaygın hastalık kategorisinde değerlendirilen 20 olgunun ise 8'i (%40) sınırlı hastalık kategorisinde tekrar evrelenmiştir (26).…”

Section: Akci̇ğer Kanserleri̇unclassified

Pet Applications For Staging And Restaging In Thoracic Malignancies

Öneş¹,

Erdıl²

2015

Toraks Cer Bult

View full text Add to dashboard Cite

In the last 10 years, Fluorine-18 fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) scan has been widely adopted in thoracic oncology, showing high accuracy in staging and restaging. The aim of this review was to focus on the results of PET scan use in the evaluation of thoracic malignancies. The literature search was performed on January 2015 in PubMed and Google Academic. The search was restricted to publications in English, using in the same string the word "PET" with different thoracic tumors. From 3000 papers initially selected, the irrelavant articles eliminated and then approximately 100 manuscripts were fully analyzed. In conclusion, positron emmision tomography/ computed tomography (PET-CT) has established itself as an important step in the evaluation of patients with thoracic malignancies. Further evaluation and come into use of newer PET tracers and simultaneous Magnetic Resonance Imaging (MRI) with PET (PET/MR) imaging will offer additional options in thoracic oncology in future.

show abstract

“…63,64 Whilst the extent of tumour enhancement post contrast is variable in SCLC, greater enhancement has been shown to be a predictor of better chemotherapeutic response, related to a greater extent of underlying tumour angiogenesis. 65 With regard to functional imaging, FDG-PET/CT has greater sensitivity and specificity for identifying metastatic lymph nodes vs conventional imaging (100% and 98% vs 70% and 94%, respectively), 66 with similar sensitivity and specificity for detecting distant metastases. 67 Ultimately, FDG-PET/CT has been shown to upstage tumours relative to CT or FDG-PET alone and has become an important adjunct in the staging and follow-up of SCLC.…”

Section: Imaging Featuresmentioning

confidence: 99%

Cardiothoracic manifestations of neuroendocrine tumours

Mandegaran¹,

David²,

Screaton³

2016

BJR

View full text Add to dashboard Cite

Cardiothoracic neuroendocrine tumour (NET) manifestations encompass a vast disease spectrum. Pulmonary neuroendocrine tumours represent a range of tumour grade and differentiation characteristics from pre-malignant diffuse neuroendocrine cell hyperplasia, well-differentiated, low-grade carcinoid tumours with excellent outcomes, through to high-grade small-cell lung carcinoma and large-cell neuroendocrine carcinoma with poor prognoses. Rarer thymic NETs represent a similarly wide neoplastic spectrum. Cardiac carcinoid is a paraneoplastic manifestation of the carcinoid syndrome and often the cause of mortality in NETs with hepatic metastases. Cardiothoracic NET manifestations are reviewed herein from a radiologists' perspective, discussing the diverse clinical presentations, spectrum of neoplastic and paraneoplastic manifestations, imaging features and treatment options.

show abstract

Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer

Abstract: The introduction of FDG-PET in the diagnostic evaluation of SCLC will improve the staging results and affect patient management, and may reduce the number of tests and invasive procedures.

Cited by 211 publications

References 24 publications

New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases

New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases

Pet Applications For Staging And Restaging In Thoracic Malignancies

Cardiothoracic manifestations of neuroendocrine tumours

Contact Info

Product

Resources

About